Why IMU is a multi multi bagger, page-28267

this is for nextHERIZON study, NCT05311176, good thing is median survival is now 6.93 months in the HER-Vaxx group versus 6.01 months in the chemotherapy alone group, Median OS was 13.9 months in the HER-Vaxx plus chemotherapy group compared to 8.3 months in the chemotherapy alone group, which indicates a 42% survival benefit and about immunogenicity

1. vaccine helped immune system to produce specific proteins called antibodies that target the HER2 protein, this is often found in large amounts on cancer cells. This response was especially strong after patients received three or more doses of the vaccine.

2. antibodies generated by the vaccine were linked to a reduction in tumor size.

3. antibodies acted like "flags," marking the cancer cells so that the body’s immune cells could find and destroy them

4. antibodies produced by the vaccine blocked certain "on" signals in the HER2 protein

5. The vaccine also reduced the number of a specific type of immune-suppressing cells called FOXP3+ T cells that normally protect the cancer. By lowering these cells, the body’s immune system was better able to fight the cancer

so overall this is awesome story line, lets see how this translates to share price appreciation.. this is good, this is good..